World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
86
Citations
43703
World Ranking
13866
National Ranking
47

Overview

Do-Youn Oh is affiliated with Seoul National University in South Korea and has contributed extensively to the field of medicine, particularly oncology. Their research spans multiple subfields, including pulmonary and respiratory medicine, surgery, molecular biology, and radiology, nuclear medicine, and imaging.

The scientist's work focuses prominently on cancer-related topics. Main areas of study include cholangiocarcinoma and gallbladder cancer, gastric cancer management and outcomes, pancreatic and hepatic oncology, cancer immunotherapy and biomarkers, colorectal cancer treatments, peptidase inhibition and analysis, and gastrointestinal tumor research and treatment.

Selected recent publications authored or co-authored by Do-Youn Oh include:

  • Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer, 2022, NEJM Evidence
  • Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study, 2020, The Lancet Oncology
  • Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study, 2020, The Lancet Oncology
  • Biliary tract cancer, 2021, The Lancet
  • Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial, 2022, The Lancet Oncology

Frequent co-authors in their work include:

  • Sun Young Rha
  • Teresa Macarulla
  • Jeesun Yoon
  • Jin Won Kim
  • Joon Oh Park

Do-Youn Oh has published in several notable scientific venues, with a significant number of works appearing in:

  • Journal of Clinical Oncology
  • Cancer Research
  • Annals of Oncology
  • The Lancet Oncology
  • Cancer Research and Treatment

Their research output highlights a sustained engagement with multiple dimensions of oncology and medical research, contributing to advancements in treatments and clinical understanding of various cancer types.

Best Publications

  • Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

    Sunil Verma;David Miles;Luca Gianni;Ian E. Krop

  • Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

    Yoon Koo Kang;Narikazu Boku;Taroh Satoh;Min Hee Ryu

  • Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

    Talia Golan;Pascal Hammel;Michele Reni;Eric Van Cutsem

  • Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

    Ghassan K. Abou-Alfa;Ghassan K. Abou-Alfa;Vaibhav Sahai;Antoine Hollebecque;Gina Vaccaro

  • Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study

    James C. Yao;Nicola Fazio;Simron Singh;Roberto Buzzoni

  • Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib

    Sae-Won Han;Tae-You Kim;Pil Gyu Hwang;Soohyun Jeong

  • HER2-targeted therapies — a role beyond breast cancer

    Do Youn Oh;Yung Jue Bang

  • Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

    Ghassan K. Abou-Alfa;Ghassan K. Abou-Alfa;Teresa Macarulla;Milind M. Javle;Robin K. Kelley

  • Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

    Milind Javle;Maeve Lowery;Rachna T. Shroff;Karl Heinz Weiss

  • Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial.

    Jin Young Jang;Youngmin Han;Hongeun Lee;Sun Whe Kim

  • Biliary tract cancer

    Juan W. Valle;Juan W. Valle;R. Katie Kelley;Bruno Nervi;Do Youn Oh

  • Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.

    Eileen M. O'Reilly;Do Youn Oh;Neesha Dhani;Daniel J. Renouf

  • A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas

    Jeffrey R. Infante;Bradley G. Somer;Joon Oh Park;Chung-Pin Li;Chung-Pin Li

  • Efficacy and Safety of Pembrolizumab for the Treatment of Advanced Biliary Cancer: Results From the KEYNOTE-158 and KEYNOTE-028 Studies

    Sarina A. Piha-Paul;Do Youn Oh;Makoto Ueno;David Malka

  • Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.

    Andrew X. Zhu;Teresa Macarulla;Milind M. Javle;R. Kate Kelley

  • Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis.

    Bhumsuk Keam;Seock-Ah Im;Kyung-Hun Lee;Sae-Won Han

  • Skeletal Muscle Depletion Predicts the Prognosis of Patients with Advanced Pancreatic Cancer Undergoing Palliative Chemotherapy, Independent of Body Mass Index.

    Younak Choi;Do-Youn Oh;Tae-Yong Kim;Kyung-Hun Lee

  • First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors

    Yung-Jue Bang;G. Giaccone;S. A. Im;D. Y. Oh

  • A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data

    Li Tzong Chen;Taroh Satoh;Min Hee Ryu;Yee Chao

  • Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.

    Bhumsuk Keam;Seock-Ah Im;Hee-Jun Kim;Do-Youn Oh

Frequent Co-Authors

Seock-Ah Im
Seock-Ah Im Seoul National University Hospital
Yung-Jue Bang
Yung-Jue Bang Seoul National University
Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital
Dong-Young Noh
Dong-Young Noh Seoul National University
Dae Seog Heo
Dae Seog Heo Seoul National University Hospital
Se-Hoon Lee
Se-Hoon Lee Sungkyunkwan University
Woo Kyung Moon
Woo Kyung Moon Seoul National University Hospital
Woo Ho Kim
Woo Ho Kim Seoul National University
Jae-Gahb Park
Jae-Gahb Park National Cancer Center
Yoon Kyung Jeon
Yoon Kyung Jeon Seoul National University Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternatives to traditional medical degrees can open up a variety of rewarding healthcare careers. For students interested in management and leadership roles, pursuing a health administration degree online is an excellent option. This pathway offers accelerated learning and the flexibility to study from anywhere.

Registered nurses aiming to advance their qualifications can enroll in asn to np bridge programs. These programs prepare nurses to become nurse practitioners, enabling them to provide a higher level of patient care and often command higher salaries.

If your interest lies in diet and wellness, some of the best online nutrition programs can help launch a career in nutrition counseling, community outreach, or research—all in a flexible, online format.

Finally, those seeking advanced roles in healthcare management might consider enrolling in one of the top cahme-accredited mha programs. Accreditation ensures high-quality education and is valued by employers nationwide.

Best Scientists Citing Do-Youn Oh

Trending Scientists

Recently Published Articles